AR087210A2 - Formulacion farmaceutica de la sal sodica del telmisartan - Google Patents
Formulacion farmaceutica de la sal sodica del telmisartanInfo
- Publication number
- AR087210A2 AR087210A2 ARP120102583A ARP120102583A AR087210A2 AR 087210 A2 AR087210 A2 AR 087210A2 AR P120102583 A ARP120102583 A AR P120102583A AR P120102583 A ARP120102583 A AR P120102583A AR 087210 A2 AR087210 A2 AR 087210A2
- Authority
- AR
- Argentina
- Prior art keywords
- telmisartan
- sodium salt
- composition
- benzimidazol
- pharmaceutical formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Formulación medicamentosa de la sal sódica cristalina del 4’-[[2-n-propil-4-metil-6-(1-metil-bencimidazol-2-il)-bencimidazol-1-ilmetil]-bifenil-2-carboxílico (telmisartán), así como procedimientos para su preparación.Reivindicación 1: Composición farmacéutica, caracterizada porque contiene la sal sódica del telmisartán y un agente diurético. Reivindicación 4: La composición de las reivindicaciones 1 a 3, caracterizada porque contiene el agente diurético hidroclorotiazida (HCTZ). Reivindicación 12: La composición de la reivindicación 1, caracterizada porque las sustancias activas se presentan como masa comprimida de un granulado seco de la sal sódica del telmisartán, que contiene las sustancias coadyuvantes manitol, estearato de magnesio e hidroxipropilcelulosa con una mezcla de hidroclorotiazida, manitol, celulosa microcristalina y almidón glicolato de sodio. Reivindicación 13: La composición de la reivindicación 1 o la reivindicación 3, caracterizada porque junto a la sal sódica del telmisartán se incorporan otras sustancias activas farmacéuticas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10319450A DE10319450A1 (de) | 2003-04-30 | 2003-04-30 | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087210A2 true AR087210A2 (es) | 2014-02-26 |
Family
ID=33305059
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101480A Pending AR044142A1 (es) | 2003-04-30 | 2004-04-30 | Formulacion farmaceutica de la sal sodica del telmisartan |
| ARP120102583A AR087210A2 (es) | 2003-04-30 | 2012-07-17 | Formulacion farmaceutica de la sal sodica del telmisartan |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101480A Pending AR044142A1 (es) | 2003-04-30 | 2004-04-30 | Formulacion farmaceutica de la sal sodica del telmisartan |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1622612B9 (es) |
| JP (2) | JP5156231B2 (es) |
| KR (1) | KR20060008943A (es) |
| CN (1) | CN100589802C (es) |
| AR (2) | AR044142A1 (es) |
| AT (1) | ATE388703T1 (es) |
| AU (1) | AU2004233581B2 (es) |
| BR (1) | BRPI0409809A (es) |
| CA (1) | CA2524091C (es) |
| CL (1) | CL2004000899A1 (es) |
| DE (2) | DE10319450A1 (es) |
| DK (1) | DK1622612T3 (es) |
| ES (1) | ES2303634T4 (es) |
| IL (1) | IL171465A (es) |
| MX (1) | MXPA05011647A (es) |
| NZ (1) | NZ543775A (es) |
| PE (1) | PE20050464A1 (es) |
| RU (1) | RU2372918C2 (es) |
| TW (1) | TWI364278B (es) |
| UY (1) | UY28293A1 (es) |
| WO (1) | WO2004096215A1 (es) |
| ZA (1) | ZA200507223B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10319450A1 (de) * | 2003-04-30 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
| DE10319592A1 (de) * | 2003-05-02 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Behandlung von diabetischer Retinopathie mit Angiotensin II-Rezeptorblockern |
| US7943781B2 (en) | 2004-10-18 | 2011-05-17 | Dr. Reddy's Laboratories Limited | Process for preparing telmisartan |
| US8637078B2 (en) | 2005-11-24 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Bilayer tablet comprising telmisartan and diuretic |
| SI2269583T1 (sl) | 2006-06-16 | 2014-12-31 | Lek Pharmaceuticals D.D. | Farmacevtski pripravek, ki vsebuje hidroklorotiazid in telmisartan |
| TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
| WO2009058950A2 (en) * | 2007-10-30 | 2009-05-07 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide |
| DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
| CZ301299B6 (cs) | 2008-11-24 | 2010-01-06 | Zentiva, A.S. | Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem |
| SI2443094T1 (sl) | 2009-06-19 | 2013-08-30 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postopek za pripravo telmisartana |
| EP2448575A2 (en) * | 2009-07-02 | 2012-05-09 | Bilgic Mahmut | Pharmaceutical composition increasing solubility and stability |
| JP2011136908A (ja) * | 2009-12-25 | 2011-07-14 | Kyowa Yakuhin Kogyo Kk | アンギオテンシンｉｉ受容体拮抗剤を含む固形製剤および固形製剤におけるアンギオテンシンｉｉ受容体拮抗剤の保存安定性向上方法 |
| CA2706292A1 (en) * | 2010-05-28 | 2011-11-28 | Pharmascience Inc. | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide |
| WO2011161123A2 (en) | 2010-06-21 | 2011-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Multilayer pharmaceutical tablet comprising telmisartan and a diuretic |
| PT2640371T (pt) * | 2010-11-15 | 2020-04-17 | Boehringer Ingelheim Int | Terapia antidiabética vasoprotetora e cardioprotetora |
| US9446032B2 (en) * | 2011-08-26 | 2016-09-20 | Wockhardt Limited | Methods for treating cardiovascular disorders |
| CN102526037B (zh) * | 2012-02-10 | 2014-08-27 | 重庆康刻尔制药有限公司 | 一种替米沙坦药物组合、片剂及其制备方法 |
| EP2649996A1 (en) * | 2012-04-11 | 2013-10-16 | Laboratorios Del. Dr. Esteve, S.A. | Crystalline forms of sartans like telmisartan with beta blockers |
| JP6018420B2 (ja) * | 2012-06-05 | 2016-11-02 | ニプロ株式会社 | アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物 |
| JP6428340B2 (ja) * | 2014-05-23 | 2018-11-28 | ニプロ株式会社 | テルミサルタンを含む医薬組成物の造粒方法 |
| JP5956034B1 (ja) * | 2015-07-27 | 2016-07-20 | エルメッド エーザイ株式会社 | テルミサルタン含有医薬組成物 |
| CN107501192A (zh) * | 2017-08-15 | 2017-12-22 | 中国科学院上海药物研究所 | 替米沙坦与氢氯噻嗪的共晶 |
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI9210098B (sl) * | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| JP4107831B2 (ja) * | 2000-11-21 | 2008-06-25 | 第一三共株式会社 | 医薬組成物 |
| US20040242891A1 (en) * | 2001-10-26 | 2004-12-02 | Jonathan Campbell | Production of keto acids |
| DE10153737A1 (de) * | 2001-10-31 | 2003-05-28 | Boehringer Ingelheim Pharma | Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
| EA007614B1 (ru) * | 2002-01-16 | 2006-12-29 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Двухслойная фармацевтическая таблетка и способ ее получения |
| DE10244681A1 (de) * | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung |
| DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
| DE10319450A1 (de) * | 2003-04-30 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
-
2003
- 2003-04-30 DE DE10319450A patent/DE10319450A1/de not_active Withdrawn
-
2004
- 2004-04-27 AU AU2004233581A patent/AU2004233581B2/en not_active Ceased
- 2004-04-27 KR KR1020057020575A patent/KR20060008943A/ko active Search and Examination
- 2004-04-27 JP JP2006500100A patent/JP5156231B2/ja not_active Expired - Fee Related
- 2004-04-27 ES ES04729635T patent/ES2303634T4/es not_active Expired - Lifetime
- 2004-04-27 AT AT04729635T patent/ATE388703T1/de active
- 2004-04-27 RU RU2005137031/15A patent/RU2372918C2/ru not_active IP Right Cessation
- 2004-04-27 EP EP04729635A patent/EP1622612B9/de not_active Expired - Lifetime
- 2004-04-27 DK DK04729635T patent/DK1622612T3/da active
- 2004-04-27 CN CN200480011725A patent/CN100589802C/zh not_active Expired - Fee Related
- 2004-04-27 NZ NZ543775A patent/NZ543775A/en not_active IP Right Cessation
- 2004-04-27 WO PCT/EP2004/004425 patent/WO2004096215A1/de active IP Right Grant
- 2004-04-27 DE DE502004006500T patent/DE502004006500D1/de not_active Expired - Lifetime
- 2004-04-27 BR BRPI0409809-9A patent/BRPI0409809A/pt not_active Application Discontinuation
- 2004-04-27 CA CA2524091A patent/CA2524091C/en not_active Expired - Fee Related
- 2004-04-27 MX MXPA05011647A patent/MXPA05011647A/es active IP Right Grant
- 2004-04-28 PE PE2004000417A patent/PE20050464A1/es not_active Application Discontinuation
- 2004-04-28 UY UY28293A patent/UY28293A1/es not_active Application Discontinuation
- 2004-04-28 CL CL200400899A patent/CL2004000899A1/es unknown
- 2004-04-29 TW TW093112090A patent/TWI364278B/zh not_active IP Right Cessation
- 2004-04-30 AR ARP040101480A patent/AR044142A1/es active Pending
-
2005
- 2005-09-08 ZA ZA200507223A patent/ZA200507223B/en unknown
- 2005-10-19 IL IL171465A patent/IL171465A/en not_active IP Right Cessation
-
2010
- 2010-03-16 JP JP2010059404A patent/JP5254268B2/ja not_active Expired - Fee Related
-
2012
- 2012-07-17 AR ARP120102583A patent/AR087210A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087210A2 (es) | Formulacion farmaceutica de la sal sodica del telmisartan | |
| AR090143A2 (es) | Composicion farmaceutica para inhibir el crecimiento de celulas anormales | |
| CO6311007A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas | |
| ECSP055733A (es) | Tabletas dispersables de deferacirox | |
| CO6311006A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas | |
| PE20061449A1 (es) | Composiciones farmaceuticas comprendiendo imatinib y un retardador de liberacion | |
| PE20130589A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a | |
| AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
| ES2054813T3 (es) | Formulacion de acetaminofen de liberacion sostenida por via oral y procedimiento para obtenerla. | |
| PE20142192A1 (es) | Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina ii y/o diuretico | |
| CY1109910T1 (el) | Χρηση μιας υδροφιλης μητρας η οποια περιεχει ενα παραγωγο πολυακρυλικου οξεος, εναν αιθερα κυτταρινης και εναν παραγοντα αποσαθρωσης για την παραγωγη ενος φαρμακου για την αγωγη ασθενειων των γυναικειων γεννητικων οργανων | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| BR112012020731A2 (pt) | pastilhas gelatinosas suaves com nicotina. | |
| MY139086A (en) | Use of debranched starch in extrusion-spheronization pharmaceutical pellets | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| AR061166A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilferina | |
| CL2011000625A1 (es) | Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida. | |
| UY27520A1 (es) | Sal sódica cristalina, procedimiento para su preparación y su uso para la preparación de un medicamento | |
| AR048864A1 (es) | Tabletas dispersables que comprenden un derivado de acido benzoico | |
| PE20030323A1 (es) | Composicion farmaceutica | |
| AR079409A1 (es) | Preparaciones antihelminticas granuladas y sistemas de suninistros | |
| PE20061390A1 (es) | Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas | |
| PE20050488A1 (es) | Formas de administracion masticables, no comprimidas, dosificadas individualmente | |
| CO2022016153A2 (es) | Inhibidores de il4i1 y métodos de uso | |
| PE20091900A1 (es) | Una formulacion farmaceutica solida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |